News about Clinical Trials

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

The company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.

Clinical Trials | 16/01/2025 | By Aishwarya |  108

CARsgen Initiates Investigator-Initiated Trial for Allogeneic CD19/CD20 CAR-T Therapy

KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases.

Clinical Trials | 02/01/2025 | By Aishwarya |  130

CStone Submits Clinical Trial Application in Australia for CS2009

CS2009 features an innovative molecular design that targets PD-1, VEGFA, and CTLA-4 simultaneously, maintaining balanced affinity for PD-1 and CTLA-4.

Clinical Trials | 23/12/2024 | By Aishwarya

Pharming Unveils Positive Topline Data in Pediatric Clinical Trial of Leniolisib

Pharming plans to include data from this 4-11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025.

Clinical Trials | 13/12/2024 | By Aishwarya

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300

The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations.

Clinical Trials | 10/12/2024 | By Aishwarya

Epigenic Therapeutics to Initiate Clinical Development of EPI-003

This first-in-human study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EPI-003 in Nucleos(t)ide Analogue-Treated, Chronic Hepatitis B Patients.

Clinical Trials | 20/11/2024 | By Aishwarya |  120

GlycoNex Signs Manufacturing Deal with Sterling for GNX102-ADC Clinical Trial Production

GNX102-ADC combines GlycoNex's proprietary monoclonal antibody (mAb), GNX102, and cytotoxic drug therapies to elicit cellular cytotoxicity to target cancer cells with high specificity.

Clinical Trials | 13/11/2024 | By Aishwarya |  170

Shuttle Pharma Finalizes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine

Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.

Clinical Trials | 29/10/2024 | By Aishwarya |  134

Unravel Biosciences and PECET to Conduct Clinical Trials of RVL-001 in Rett Syndrome in Colombia

Unravel's proprietary BioNAV drug discovery platform identified RVL-001 as a potentially promising therapeutic drug for Rett Syndrome and PTHS.

Clinical Trials | 25/10/2024 | By Aishwarya |  185

Evergreen Theragnostics Opens Phase II Small Cell Lung Cancer Clinical Trial in EU

The CCK2-VIEW trial uses 68Ga-EVG321, a peptide-based Radioligand imaging agent administered to patients with small cell lung cancer.

Clinical Trials | 18/10/2024 | By Aishwarya |  115